Dosing Reference Table

Comprehensive research dosing reference for 20+ popular peptides. All information is derived from published preclinical studies and manufacturer guidelines.

Peptide Name	Category	Typical Dose Range	Frequency	Reconstitution	Storage	Shelf Life	Notes
5-Amino-1MQ	Fat Loss	50–100 mg (oral)	1–2x daily	N/A (capsule)	Room temp, dry	12 months (capsule)	NNMT inhibitor. Oral small molecule, not a peptide. Increases NAD+ levels.
AOD-9604	Fat Loss	300–600 mcg	1x daily (fasting)	2 mL per 5 mg vial	2–8°C	28 days	hGH fragment 176-191. Lipolytic without hyperglycemic effects.
BPC-157	Healing & Recovery	200–300 mcg	1–2x daily	2 mL per 5 mg vial	2–8°C	28 days	Subcutaneous near injury site in preclinical models. Stable peptide.
CJC-1295 (no DAC)	Hormonal	100–300 mcg	1–3x daily	2 mL per 2 mg vial	2–8°C	21 days	Best administered with a GHRP for synergistic GH release.
CJC-1295 (with DAC)	Hormonal	1–2 mg	1–2x weekly	2 mL per 2 mg vial	2–8°C	21 days	Long-acting due to DAC (drug affinity complex). Sustained GH elevation.
Dihexa	Nootropic	10–20 mg (oral)	1x daily	N/A (capsule)	Room temp, dry	12 months (capsule)	HGF receptor agonist. Extremely potent — 10 million times more potent than BDNF in vitro.
DSIP	Performance	100–300 mcg	1x daily (evening)	2 mL per 5 mg vial	2–8°C	21 days	Delta sleep-inducing peptide. Modulates sleep architecture and stress hormones.
Epithalon	Performance	5–10 mg	1x daily for 10–20 day cycles	2 mL per 10 mg vial	2–8°C	28 days	Telomerase activator. Cycled 10–20 days on, 4–6 months off in research.
GHK-Cu	Healing & Recovery	200–600 mcg	1x daily	2 mL per 10 mg vial	2–8°C	21 days	Copper-peptide complex. Sensitive to oxidation — minimize air exposure.
GHRP-2	Hormonal	100–300 mcg	2–3x daily	2.5 mL per 5 mg vial	2–8°C	28 days	Stronger GH release than Ipamorelin. May increase appetite and cortisol mildly.
GHRP-6	Hormonal	100–300 mcg	2–3x daily	2.5 mL per 5 mg vial	2–8°C	28 days	Potent appetite stimulation. Strong GH release. Cardioprotective in preclinical data.
Hexarelin	Hormonal	100–200 mcg	2–3x daily	2 mL per 5 mg vial	2–8°C	28 days	Most potent GHRP. Significant cortisol and prolactin elevation at higher doses.
HGH Fragment 176-191	Fat Loss	250–500 mcg	1–2x daily (fasting)	2 mL per 5 mg vial	2–8°C	28 days	C-terminal fragment of hGH. Similar mechanism to AOD-9604.
Ipamorelin	Hormonal	200–300 mcg	2–3x daily	2.5 mL per 5 mg vial	2–8°C	28 days	Most selective GHRP. No significant effect on cortisol, prolactin, or appetite.
KPV	Healing & Recovery	200–500 mcg	1x daily	2 mL per 5 mg vial	2–8°C	28 days	Alpha-MSH fragment. Anti-inflammatory focus in preclinical GI research.
LL-37	Healing & Recovery	50–100 mcg	1x daily	2 mL per 5 mg vial	2–8°C	14 days	Cathelicidin antimicrobial peptide. Handle with care — less stable once reconstituted.
PT-141	Hormonal	500–1000 mcg	As needed (not daily)	2 mL per 10 mg vial	2–8°C	28 days	Melanocortin receptor agonist. Effects last 24–72 hours. Nausea possible at high doses.
Selank	Nootropic	250–500 mcg	1–3x daily	2 mL per 5 mg vial	2–8°C	21 days	Intranasal or subcutaneous. Tuftsin analog with anxiolytic and immunomodulatory effects.
Semax	Nootropic	200–600 mcg	1–2x daily	2 mL per 5 mg vial	2–8°C	21 days	ACTH(4-10) analog. Neuroprotective. Intranasal is common route in research.
TB-500	Healing & Recovery	2–2.5 mg	2x weekly (loading), 1x weekly (maintenance)	2 mL per 5 mg vial	2–8°C	28 days	Loading phase typically 4–6 weeks in research protocols.
Tesamorelin	Fat Loss	1–2 mg	1x daily	2 mL per 2 mg vial	2–8°C	14 days	FDA-recognized GHRH analog. Primary research focus on visceral adiposity reduction.
Thymosin Alpha-1	Performance	1.6 mg	2x weekly	1 mL per 5 mg vial	2–8°C	28 days	Immunomodulatory peptide. Well-characterized safety profile. FDA orphan drug.

Showing 22 of 22 peptides

Disclaimer: This table is for research reference only. All dosing information is derived from published preclinical studies and manufacturer documentation. These products are sold strictly for in-vitro research and laboratory use. They are not intended for human consumption. Consult published literature and institutional review protocols before designing any research protocol.